CIK 0001501756
ADVM Adverum Biotechnologies, Inc.
Insider trading from SEC Form 4. Last filing Jun 20, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
15
with a Form 4 at this company
Signals
Open-market buys and sells at Adverum Biotechnologies, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Laurent Fischer CEO, PRESIDENT AND DIRECTOR sell | $18k 9,126 shares | -9% | - | |
| 30Weak | Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER sell | $1,848 924 shares | -6% | - | |
| 35Weak | Peter Soparkar CHIEF OPERATING OFFICER sell | $5,920 2,960 shares | -7% | - | |
| 30Weak | Braden Michael Leonard owner buy | $189k 37,000 shares | +35% | - | |
| 30Weak | Braden Michael Leonard owner buy | $189k 37,000 shares | +35% | - | |
| 40Moderate | Braden Michael Leonard owner buy | $1.0M 350,000 shares | +13% | - | |
| 23Weak | Braden Michael Leonard owner buy | $147k 34,775 shares | +1% | - | |
| 30Weak | Braden Michael Leonard owner buy | $189k 37,000 shares | +35% | - | |
| 31Weak | Braden Michael Leonard owner buy | $588k 117,941 shares | +5% | - | |
| 35Weak | Braden Michael Leonard owner buy | $1.4M 336,756 shares | +15% | - |
Transactions
The last 88 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 17, 2025 | Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER | DDisposition to issuer Stock Option (Right to Buy)derivative | -42,500 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 17, 2025 | Peter Soparkar CHIEF OPERATING OFFICER | DDisposition to issuer Stock Option (Right to Buy)derivative | -40,000 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 17, 2025 | Patrick Machado director | AGrant or award Stock Option (Right to Buy)derivative | +10,450 | $0.00 | $0 | 10,450 | Jun 20, 2025 |
| Jun 17, 2025 | Rabia Gurses Ozden Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -8,000 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 17, 2025 | Linda M Rubinstein CHIEF FINANCIAL OFFICER | DDisposition to issuer Stock Option (Right to Buy)derivative | -85,000 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 17, 2025 | Laurent Fischer CEO, PRESIDENT AND DIRECTOR | DDisposition to issuer Stock Option (Right to Buy)derivative | -120,000 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 17, 2025 | Szilard Kiss director | AGrant or award Stock Option (Right to Buy)derivative | +10,450 | $0.00 | $0 | 10,450 | Jun 20, 2025 |
| Jun 17, 2025 | James Paul Scopa director | AGrant or award Stock Option (Right to Buy)derivative | +10,450 | $0.00 | $0 | 10,450 | Jun 20, 2025 |
| Jun 17, 2025 | Scott M Whitcup director | AGrant or award Stock Option (Right to Buy)derivative | +10,450 | $0.00 | $0 | 10,450 | Jun 20, 2025 |
| Jun 17, 2025 | Reed Vaughn Tuckson director | AGrant or award Stock Option (Right to Buy)derivative | +10,450 | $0.00 | $0 | 10,450 | Jun 20, 2025 |
| Jun 17, 2025 | Dawn Svoronos director | AGrant or award Stock Option (Right to Buy)derivative | +10,450 | $0.00 | $0 | 10,450 | Jun 20, 2025 |
| Jun 17, 2025 | Jr. Mark L. Lupher director | AGrant or award Stock Option (Right to Buy)derivative | +10,450 | $0.00 | $0 | 10,450 | Jun 20, 2025 |
| Jun 17, 2025 | Soo Hong director | AGrant or award Stock Option (Right to Buy)derivative | +10,450 | $0.00 | $0 | 10,450 | Jun 20, 2025 |
| Jun 17, 2025 | C. David Nicholson director | AGrant or award Stock Option (Right to Buy)derivative | +10,450 | $0.00 | $0 | 10,450 | Jun 20, 2025 |
| Jun 17, 2025 | Linda M Rubinstein CHIEF FINANCIAL OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +85,000 | $0.00 | $0 | 85,000 | Jun 20, 2025 |
| Jun 17, 2025 | Rabia Gurses Ozden Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +8,000 | $0.00 | $0 | 8,000 | Jun 20, 2025 |
| Jun 17, 2025 | Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +42,500 | $0.00 | $0 | 42,500 | Jun 20, 2025 |
| Jun 17, 2025 | Patrick Machado director | AGrant or award Stock Option (Right to Buy)derivative | +3,140 | $0.00 | $0 | 3,140 | Jun 20, 2025 |
| Jun 17, 2025 | Peter Soparkar CHIEF OPERATING OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jun 20, 2025 |
| Jun 17, 2025 | Laurent Fischer CEO, PRESIDENT AND DIRECTOR | AGrant or award Stock Option (Right to Buy)derivative | +120,000 | $0.00 | $0 | 120,000 | Jun 20, 2025 |
| Jun 17, 2025 | Peter Soparkar CHIEF OPERATING OFFICER | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,074 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 17, 2025 | Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER | DDisposition to issuer Stock Option (Right to Buy)derivative | -8,500 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 17, 2025 | Rabia Gurses Ozden Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,000 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 17, 2025 | Laurent Fischer CEO, PRESIDENT AND DIRECTOR | DDisposition to issuer Stock Option (Right to Buy)derivative | -68,000 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 17, 2025 | Linda M Rubinstein CHIEF FINANCIAL OFFICER | DDisposition to issuer Stock Option (Right to Buy)derivative | -35,000 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 17, 2025 | Peter Soparkar CHIEF OPERATING OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +4,074 | $0.00 | $0 | 4,074 | Jun 20, 2025 |
| Jun 17, 2025 | Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +8,500 | $0.00 | $0 | 8,500 | Jun 20, 2025 |
| Jun 17, 2025 | Laurent Fischer CEO, PRESIDENT AND DIRECTOR | AGrant or award Stock Option (Right to Buy)derivative | +68,000 | $0.00 | $0 | 68,000 | Jun 20, 2025 |
| Jun 17, 2025 | Rabia Gurses Ozden Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +4,000 | $0.00 | $0 | 4,000 | Jun 20, 2025 |
| Jun 17, 2025 | Linda M Rubinstein CHIEF FINANCIAL OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +35,000 | $0.00 | $0 | 35,000 | Jun 20, 2025 |
| Jun 17, 2025 | Peter Soparkar CHIEF OPERATING OFFICER | DDisposition to issuer Stock Option (Right to Buy)derivative | -13,999 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 10, 2025 | Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER | DDisposition to issuer Stock Option (Right to Buy)derivative | -40,000 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 17, 2025 | Laurent Fischer CEO, PRESIDENT AND DIRECTOR | DDisposition to issuer Stock Option (Right to Buy)derivative | -45,499 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 17, 2025 | Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jun 20, 2025 |
| Jun 17, 2025 | Peter Soparkar CHIEF OPERATING OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +13,999 | $0.00 | $0 | 13,999 | Jun 20, 2025 |
| Jun 17, 2025 | Laurent Fischer CEO, PRESIDENT AND DIRECTOR | AGrant or award Stock Option (Right to Buy)derivative | +45,499 | $0.00 | $0 | 45,499 | Jun 20, 2025 |
| Jun 17, 2025 | Laurent Fischer CEO, PRESIDENT AND DIRECTOR | DDisposition to issuer Stock Option (Right to Buy)derivative | -63,000 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 17, 2025 | Peter Soparkar CHIEF OPERATING OFFICER | DDisposition to issuer Stock Option (Right to Buy)derivative | -15,999 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 17, 2025 | Laurent Fischer CEO, PRESIDENT AND DIRECTOR | AGrant or award Stock Option (Right to Buy)derivative | +63,000 | $0.00 | $0 | 63,000 | Jun 20, 2025 |
| Jun 17, 2025 | Peter Soparkar CHIEF OPERATING OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +15,999 | $0.00 | $0 | 15,999 | Jun 20, 2025 |
| Jun 17, 2025 | Laurent Fischer CEO, PRESIDENT AND DIRECTOR | DDisposition to issuer Stock Option (Right to Buy)derivative | -31,500 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 17, 2025 | Peter Soparkar CHIEF OPERATING OFFICER | DDisposition to issuer Stock Option (Right to Buy)derivative | -25,500 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 17, 2025 | Laurent Fischer CEO, PRESIDENT AND DIRECTOR | AGrant or award Stock Option (Right to Buy)derivative | +31,500 | $0.00 | $0 | 31,500 | Jun 20, 2025 |
| Jun 17, 2025 | Peter Soparkar CHIEF OPERATING OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +25,500 | $0.00 | $0 | 25,500 | Jun 20, 2025 |
| Jun 17, 2025 | Laurent Fischer CEO, PRESIDENT AND DIRECTOR | DDisposition to issuer Stock Option (Right to Buy)derivative | -58,497 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 17, 2025 | Peter Soparkar CHIEF OPERATING OFFICER | DDisposition to issuer Stock Option (Right to Buy)derivative | -13,000 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 17, 2025 | Laurent Fischer CEO, PRESIDENT AND DIRECTOR | AGrant or award Stock Option (Right to Buy)derivative | +58,497 | $0.00 | $0 | 58,497 | Jun 20, 2025 |
| Jun 17, 2025 | Peter Soparkar CHIEF OPERATING OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +13,000 | $0.00 | $0 | 13,000 | Jun 20, 2025 |
| Jun 17, 2025 | Laurent Fischer CEO, PRESIDENT AND DIRECTOR | DDisposition to issuer Stock Option (Right to Buy)derivative | -67,502 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 17, 2025 | Peter Soparkar CHIEF OPERATING OFFICER | DDisposition to issuer Stock Option (Right to Buy)derivative | -23,092 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 17, 2025 | Laurent Fischer CEO, PRESIDENT AND DIRECTOR | AGrant or award Stock Option (Right to Buy)derivative | +67,502 | $0.00 | $0 | 67,502 | Jun 20, 2025 |
| Jun 17, 2025 | Peter Soparkar CHIEF OPERATING OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +23,092 | $0.00 | $0 | 23,092 | Jun 20, 2025 |
| Jun 17, 2025 | Laurent Fischer CEO, PRESIDENT AND DIRECTOR | DDisposition to issuer Stock Option (Right to Buy)derivative | -110,420 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 17, 2025 | Peter Soparkar CHIEF OPERATING OFFICER | DDisposition to issuer Stock Option (Right to Buy)derivative | -16,384 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 17, 2025 | Peter Soparkar CHIEF OPERATING OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +16,384 | $0.00 | $0 | 16,384 | Jun 20, 2025 |
| Jun 17, 2025 | Laurent Fischer CEO, PRESIDENT AND DIRECTOR | AGrant or award Stock Option (Right to Buy)derivative | +110,420 | $0.00 | $0 | 110,420 | Jun 20, 2025 |
| Jun 17, 2025 | Peter Soparkar CHIEF OPERATING OFFICER | DDisposition to issuer Stock Option (Right to Buy)derivative | -45,000 | $0.00 | $0 | 0 | Jun 20, 2025 |
| Jun 17, 2025 | Peter Soparkar CHIEF OPERATING OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Jun 20, 2025 |
| May 15, 2025 | Laurent Fischer CEO, PRESIDENT AND DIRECTOR | SOpen-market sale Common Stock | -9,126 | $2.00 | $18k | 87,488 | May 16, 2025 |
| May 15, 2025 | Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER | SOpen-market sale Common Stock | -924 | $2.00 | $1,848 | 13,768 | May 16, 2025 |
| May 15, 2025 | Peter Soparkar CHIEF OPERATING OFFICER | SOpen-market sale Common Stock | -2,960 | $2.00 | $5,920 | 39,154 | May 16, 2025 |
| Mar 26, 2025 | Braden Michael Leonard owner | POpen-market purchase Common Stock | +20,407 | $5.04 | $103k | 125,207 | Apr 28, 2025 |
| Mar 26, 2025 | Braden Michael Leonard owner | POpen-market purchase Common Stock | +20,407 | $5.04 | $103k | 125,207 | Apr 28, 2025 |
| Mar 27, 2025 | Braden Michael Leonard owner | POpen-market purchase Common Stock | +16,593 | $5.19 | $86k | 141,800 | Apr 28, 2025 |
| Mar 27, 2025 | Braden Michael Leonard owner | POpen-market purchase Common Stock | +16,593 | $5.19 | $86k | 141,800 | Apr 28, 2025 |
| Apr 22, 2025 | Braden Michael Leonard owner | POpen-market purchase Common Stockindirect: Holdings of BML Investment Partners, L.P. | +300,000 | $3.00 | $900k | 3,057,526 | Apr 24, 2025 |
| Apr 23, 2025 | Braden Michael Leonard owner | POpen-market purchase Common Stock | +50,000 | $2.98 | $149k | 191,800 | Apr 24, 2025 |
| Mar 31, 2025 | Braden Michael Leonard owner | POpen-market purchase Common Stockindirect: Holdings of BML Investment Partners, L.P. | +19,566 | $4.38 | $86k | 2,742,317 | Apr 2, 2025 |
| Apr 2, 2025 | Braden Michael Leonard owner | POpen-market purchase Common Stockindirect: Holdings of BML Investment Partners, L.P | +15,209 | $4.04 | $61k | 2,757,526 | Apr 2, 2025 |
| Mar 26, 2025 | Braden Michael Leonard owner | POpen-market purchase Common Stock | +20,407 | $5.04 | $103k | 125,207 | Mar 27, 2025 |
| Mar 27, 2025 | Braden Michael Leonard owner | POpen-market purchase Common Stock | -16,593 | $5.19 | $86k | 141,800 | Mar 27, 2025 |
| Mar 18, 2025 | Braden Michael Leonard owner | POpen-market purchase Common Stockindirect: Holding of BML Investment Partners, L.P. | +18,000 | $4.60 | $83k | 2,622,820 | Mar 20, 2025 |
| Mar 18, 2025 | Braden Michael Leonard owner | POpen-market purchase Common Stockindirect: Holding of BML Investment Partners, L.P. | +44,341 | $4.73 | $210k | 2,667,161 | Mar 20, 2025 |
| Mar 19, 2025 | Braden Michael Leonard owner | POpen-market purchase Common Stockindirect: Holding of BML Investment Partners, L.P. | +25,000 | $4.94 | $123k | 2,692,161 | Mar 20, 2025 |
| Mar 20, 2025 | Braden Michael Leonard owner | POpen-market purchase Common Stovkindirect: Holding of BML Investment Partners, L.P. | +30,600 | $5.61 | $172k | 2,722,761 | Mar 20, 2025 |
| Feb 26, 2025 | Braden Michael Leonard owner | POpen-market purchase Common Stockindirect: Holding of BML Investment Partners, L.P. | +164,886 | $4.01 | $661k | 2,432,950 | Feb 28, 2025 |
| Feb 27, 2025 | Braden Michael Leonard owner | POpen-market purchase Common Stockindirect: Holding of BML Investment Partners, L.P. | +86,802 | $4.46 | $387k | 2,519,752 | Feb 28, 2025 |
| Feb 28, 2025 | Braden Michael Leonard owner | POpen-market purchase Common Stockindirect: Holding of BML Investment Partners, L.P. | +85,068 | $4.60 | $391k | 2,604,820 | Feb 28, 2025 |
| Feb 25, 2025 | Laurent Fischer CEO, PRESIDENT AND DIRECTOR | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 96,614 | Feb 27, 2025 |
| Feb 25, 2025 | Rabia Gurses Ozden Chief Medical Officer | AGrant or award Common Stock | +8,125 | $0.00 | $0 | 8,125 | Feb 27, 2025 |
| Feb 25, 2025 | Linda M Rubinstein CHIEF FINANCIAL OFFICER | AGrant or award Common Stock | +8,125 | $0.00 | $0 | 19,325 | Feb 27, 2025 |
| Feb 25, 2025 | Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER | AGrant or award Common Stock | +8,125 | $0.00 | $0 | 14,692 | Feb 27, 2025 |
| Feb 25, 2025 | Peter Soparkar CHIEF OPERATING OFFICER | AGrant or award Common Stock | +13,125 | $0.00 | $0 | 42,114 | Feb 27, 2025 |
| Feb 25, 2025 | Laurent Fischer CEO, PRESIDENT AND DIRECTOR | AGrant or award Stock Option (Right to Buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Feb 27, 2025 |
| Feb 25, 2025 | Rabia Gurses Ozden Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +48,750 | $0.00 | $0 | 48,750 | Feb 27, 2025 |
| Feb 25, 2025 | Linda M Rubinstein CHIEF FINANCIAL OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +48,750 | $0.00 | $0 | 48,750 | Feb 27, 2025 |
| Feb 25, 2025 | Setareh Seyedkazemi CHIEF DEVELOPMENT OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +48,750 | $0.00 | $0 | 48,750 | Feb 27, 2025 |
| Feb 25, 2025 | Peter Soparkar CHIEF OPERATING OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +78,750 | $0.00 | $0 | 78,750 | Feb 27, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Laurent FischerCEO, PRESIDENT AND DIRECTOR
- Soo Hongdirector
- Szilard Kissdirector
- Braden Michael Leonardowner
- Jr. Mark L. Lupherdirector
- Patrick Machadodirector
- C. David Nicholsondirector
- Rabia Gurses OzdenChief Medical Officer
- Linda M RubinsteinCHIEF FINANCIAL OFFICER
- James Paul Scopadirector
- Setareh SeyedkazemiCHIEF DEVELOPMENT OFFICER
- Peter SoparkarCHIEF OPERATING OFFICER
- Dawn Svoronosdirector
- Reed Vaughn Tucksondirector
- Scott M Whitcupdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.